220 related articles for article (PubMed ID: 31151801)
1. Safety, toxicity and immunogenicity of a malaria vaccine based on the circumsporozoite protein (FMP013) with the adjuvant army liposome formulation containing QS21 (ALFQ).
Cawlfield A; Genito CJ; Beck Z; Bergmann-Leitner ES; Bitzer AA; Soto K; Zou X; Hadiwidjojo SH; Gerbasi RV; Mullins AB; Noe A; Waters NC; Alving CR; Matyas GR; Dutta S
Vaccine; 2019 Jun; 37(29):3793-3803. PubMed ID: 31151801
[TBL] [Abstract][Full Text] [Related]
2. Liposomes containing monophosphoryl lipid A and QS-21 serve as an effective adjuvant for soluble circumsporozoite protein malaria vaccine FMP013.
Genito CJ; Beck Z; Phares TW; Kalle F; Limbach KJ; Stefaniak ME; Patterson NB; Bergmann-Leitner ES; Waters NC; Matyas GR; Alving CR; Dutta S
Vaccine; 2017 Jul; 35(31):3865-3874. PubMed ID: 28596090
[TBL] [Abstract][Full Text] [Related]
3. Comparison of immunogenicity and safety outcomes of a malaria vaccine FMP013/ALFQ in rhesus macaques (Macaca mulatta) of Indian and Chinese origin.
Martin ML; Bitzer AA; Schrader A; Bergmann-Leitner ES; Soto K; Zou X; Beck Z; Matyas GR; Dutta S
Malar J; 2019 Nov; 18(1):377. PubMed ID: 31775762
[TBL] [Abstract][Full Text] [Related]
4. First-in-human assessment of safety and immunogenicity of low and high doses of Plasmodium falciparum malaria protein 013 (FMP013) administered intramuscularly with ALFQ adjuvant in healthy malaria-naïve adults.
Hutter JN; Robben PM; Lee C; Hamer M; Moon JE; Merino K; Zhu L; Galli H; Quinn X; Brown DR; Duncan E; Bolton J; Zou X; Angov E; Lanar DE; Rao M; Matyas GR; Beck Z; Bergmann-Leitner E; Soisson LA; Waters NC; Ngauy V; Regules J; Dutta S
Vaccine; 2022 Sep; 40(40):5781-5790. PubMed ID: 36055874
[TBL] [Abstract][Full Text] [Related]
5. Optimization of a
Langowski MD; Khan FA; Bitzer AA; Genito CJ; Schrader AJ; Martin ML; Soto K; Zou X; Hadiwidjojo S; Beck Z; Matyas GR; Livingstone MC; Batchelor AH; Dutta S
Proc Natl Acad Sci U S A; 2020 Feb; 117(6):3114-3122. PubMed ID: 31988134
[No Abstract] [Full Text] [Related]
6. Enhanced Immunogenicity and Protective Efficacy of a
Ramakrishnan A; Schumack NM; Gariepy CL; Eggleston H; Nunez G; Espinoza N; Nieto M; Castillo R; Rojas J; McCoy AJ; Beck Z; Matyas GR; Alving CR; Guerry P; Poly F; Laird RM
mSphere; 2019 May; 4(3):. PubMed ID: 31043512
[No Abstract] [Full Text] [Related]
7. Preclinical evaluation of the safety and immunogenicity of a vaccine consisting of Plasmodium falciparum liver-stage antigen 1 with adjuvant AS01B administered alone or concurrently with the RTS,S/AS01B vaccine in rhesus primates.
Pichyangkul S; Kum-Arb U; Yongvanitchit K; Limsalakpetch A; Gettayacamin M; Lanar DE; Ware LA; Stewart VA; Heppner DG; Mettens P; Cohen JD; Ballou WR; Fukuda MM
Infect Immun; 2008 Jan; 76(1):229-38. PubMed ID: 17954725
[TBL] [Abstract][Full Text] [Related]
8. Priming with an adenovirus 35-circumsporozoite protein (CS) vaccine followed by RTS,S/AS01B boosting significantly improves immunogenicity to Plasmodium falciparum CS compared to that with either malaria vaccine alone.
Stewart VA; McGrath SM; Dubois PM; Pau MG; Mettens P; Shott J; Cobb M; Burge JR; Larson D; Ware LA; Demoitie MA; Weverling GJ; Bayat B; Custers JH; Dubois MC; Cohen J; Goudsmit J; Heppner DG
Infect Immun; 2007 May; 75(5):2283-90. PubMed ID: 17307942
[TBL] [Abstract][Full Text] [Related]
9. Heterologous prime-boost immunization in rhesus macaques by two, optimally spaced particle-mediated epidermal deliveries of Plasmodium falciparum circumsporozoite protein-encoding DNA, followed by intramuscular RTS,S/AS02A.
Walsh DS; Gettayacamin M; Leitner WW; Lyon JA; Stewart VA; Marit G; Pichyangkul S; Gosi P; Tongtawe P; Kester KE; Holland CA; Kolodny N; Cohen J; Voss G; Ballou WR; Heppner DG
Vaccine; 2006 May; 24(19):4167-78. PubMed ID: 16574282
[TBL] [Abstract][Full Text] [Related]
10. Rhesus macaque and mouse models for down-selecting circumsporozoite protein based malaria vaccines differ significantly in immunogenicity and functional outcomes.
Phares TW; May AD; Genito CJ; Hoyt NA; Khan FA; Porter MD; DeBot M; Waters NC; Saudan P; Dutta S
Malar J; 2017 Mar; 16(1):115. PubMed ID: 28288639
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity of the RTS,S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial.
White MT; Verity R; Griffin JT; Asante KP; Owusu-Agyei S; Greenwood B; Drakeley C; Gesase S; Lusingu J; Ansong D; Adjei S; Agbenyega T; Ogutu B; Otieno L; Otieno W; Agnandji ST; Lell B; Kremsner P; Hoffman I; Martinson F; Kamthunzu P; Tinto H; Valea I; Sorgho H; Oneko M; Otieno K; Hamel MJ; Salim N; Mtoro A; Abdulla S; Aide P; Sacarlal J; Aponte JJ; Njuguna P; Marsh K; Bejon P; Riley EM; Ghani AC
Lancet Infect Dis; 2015 Dec; 15(12):1450-8. PubMed ID: 26342424
[TBL] [Abstract][Full Text] [Related]
12. Recombinant Full-length Plasmodium falciparum Circumsporozoite Protein-Based Vaccine Adjuvanted With Glucopyranosyl Lipid A-Liposome Quillaja saponaria 21: Results of Phase 1 Testing With Malaria Challenge.
Friedman-Klabanoff DJ; Berry AA; Travassos MA; Shriver M; Cox C; Butts J; Lundeen JS; Strauss KA; Joshi S; Shrestha B; Mo AX; Nomicos EYH; Deye GA; Regules JA; Bergmann-Leitner ES; Pasetti MF; Laurens MB
J Infect Dis; 2024 Jun; 229(6):1883-1893. PubMed ID: 38330357
[TBL] [Abstract][Full Text] [Related]
13. Safety and immunogenicity of rts,s+trap malaria vaccine, formulated in the as02a adjuvant system, in infant rhesus monkeys.
Walsh DS; Pichyangkul S; Gettayacamin M; Tongtawe P; Siegrist CA; Hansukjariya P; Kester KE; Holland CA; Voss G; Cohen J; Stewart AV; Miller RS; Ballou WR; Heppner DG
Am J Trop Med Hyg; 2004 May; 70(5):499-509. PubMed ID: 15155981
[TBL] [Abstract][Full Text] [Related]
14. Phase 1/2a study of the malaria vaccine candidate apical membrane antigen-1 (AMA-1) administered in adjuvant system AS01B or AS02A.
Spring MD; Cummings JF; Ockenhouse CF; Dutta S; Reidler R; Angov E; Bergmann-Leitner E; Stewart VA; Bittner S; Juompan L; Kortepeter MG; Nielsen R; Krzych U; Tierney E; Ware LA; Dowler M; Hermsen CC; Sauerwein RW; de Vlas SJ; Ofori-Anyinam O; Lanar DE; Williams JL; Kester KE; Tucker K; Shi M; Malkin E; Long C; Diggs CL; Soisson L; Dubois MC; Ballou WR; Cohen J; Heppner DG
PLoS One; 2009; 4(4):e5254. PubMed ID: 19390585
[TBL] [Abstract][Full Text] [Related]
15. Poly(I:C) is an effective adjuvant for antibody and multi-functional CD4+ T cell responses to Plasmodium falciparum circumsporozoite protein (CSP) and αDEC-CSP in non human primates.
Tewari K; Flynn BJ; Boscardin SB; Kastenmueller K; Salazar AM; Anderson CA; Soundarapandian V; Ahumada A; Keler T; Hoffman SL; Nussenzweig MC; Steinman RM; Seder RA
Vaccine; 2010 Oct; 28(45):7256-66. PubMed ID: 20846528
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial.
Datoo MS; Natama MH; Somé A; Traoré O; Rouamba T; Bellamy D; Yameogo P; Valia D; Tegneri M; Ouedraogo F; Soma R; Sawadogo S; Sorgho F; Derra K; Rouamba E; Orindi B; Ramos Lopez F; Flaxman A; Cappuccini F; Kailath R; Elias S; Mukhopadhyay E; Noe A; Cairns M; Lawrie A; Roberts R; Valéa I; Sorgho H; Williams N; Glenn G; Fries L; Reimer J; Ewer KJ; Shaligram U; Hill AVS; Tinto H
Lancet; 2021 May; 397(10287):1809-1818. PubMed ID: 33964223
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of the RTS,S/AS01E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial.
Asante KP; Abdulla S; Agnandji S; Lyimo J; Vekemans J; Soulanoudjingar S; Owusu R; Shomari M; Leach A; Jongert E; Salim N; Fernandes JF; Dosoo D; Chikawe M; Issifou S; Osei-Kwakye K; Lievens M; Paricek M; Möller T; Apanga S; Mwangoka G; Dubois MC; Madi T; Kwara E; Minja R; Hounkpatin AB; Boahen O; Kayan K; Adjei G; Chandramohan D; Carter T; Vansadia P; Sillman M; Savarese B; Loucq C; Lapierre D; Greenwood B; Cohen J; Kremsner P; Owusu-Agyei S; Tanner M; Lell B
Lancet Infect Dis; 2011 Oct; 11(10):741-9. PubMed ID: 21782519
[TBL] [Abstract][Full Text] [Related]
18. Novel Virus-Like Particle Vaccine Encoding the Circumsporozoite Protein of
Kurtovic L; Wetzel D; Reiling L; Drew DR; Palmer C; Kouskousis B; Hanssen E; Wines BD; Hogarth PM; Suckow M; Jenzelewski V; Piontek M; Chan JA; Beeson JG
Front Immunol; 2021; 12():641421. PubMed ID: 33815393
[TBL] [Abstract][Full Text] [Related]
19. Similarities and differences of chemical compositions and physical and functional properties of adjuvant system 01 and army liposome formulation with QS21.
Alving CR; Rao M; Matyas GR
Front Immunol; 2023; 14():1102524. PubMed ID: 36761767
[TBL] [Abstract][Full Text] [Related]
20. Live attenuated rubella vectors expressing Plasmodium falciparum circumsporozoite protein (Pf-CSP) provide a novel malaria vaccine platform in the rhesus macaque.
Virnik K; Zhou W; Medvedev A; Walsh G; Perry-Anderson J; Majam V; Felber BK; Kumar S; Berkower I
Biochem Biophys Res Commun; 2021 Nov; 577():58-63. PubMed ID: 34507066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
